EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors

Fang-Tsyr Lin iD, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi iD, Yongcheng Song, Shwu-Jiuan Lin iD, Weei-Chin Lin iD

Proceedings of the National Academy of Sciences · 31.10.2023 · 120 (44)

DOI: 10.1073/pnas.2307793120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 25.10.2023. Verfasst von Fang-Tsyr Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, HHS | NIH | National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously identified TopBP1 (topoisomerase IIβ-binding protein 1) as a promising target for cancer therapy, given its role in the convergence of Rb, PI(3)K/Akt, and p53 pathways. Based on this, we conducted a large-scale molecular docking screening to identify a small-molecule inhibitor that specifically targets the BRCT7/8 domains of TopBP1, which we have named 5D4. Our studies show that 5D4 inhibits TopBP1 interactions with E2F1, mutant p53, and Cancerous Inhibitor of Protein Phosphatase 2A. This leads to the activation of E2F1-mediated apoptosis and the inhibition of mutant p53 gain of function. In addition, 5D4 disrupts the interaction of TopBP1 with MIZ1, which in turn allows MIZ1 to bind to its target gene promoters and repress MYC activity. Moreover, 5D4 inhibits the association of the TopBP1-PLK1 complex and prevents the formation of Rad51 foci. When combined with inhibitors of PARP1/2 or PARP14, 5D4 synergizes to effectively block cancer cell proliferation. Our animal studies have demonstrated the antitumor activity of 5D4 in breast and ovarian cancer xenograft models. Moreover, the effectiveness of 5D4 is further enhanced when combined with a PARP1/2 inhibitor talazoparib. Taken together, our findings strongly support the potential use of TopBP1-BRCT7/8 inhibitors as a targeted cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsPoly(ADP-ribose) Polymerase InhibitorsAnimalsHumansTumor Suppressor Protein p53Nuclear ProteinsMolecular Docking SimulationCarrier Proteins

Stichwörter der Autor:innen

BRCT domainsMYCTopBP1p53small-molecule inhibitors

Substanzen

DNA-Binding ProteinsPoly(ADP-ribose) Polymerase InhibitorsTumor Suppressor Protein p53Nuclear ProteinsCarrier Proteins

Autor:innen und Institutionen

  • Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
  • Cancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, TX 77030.
  • Department of Pharmacology, Baylor College of Medicine, Houston, TX 77030.
  • Department of Pharmaceutical Sciences, School of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
  • PhD Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.

ORCID-Profile: Fang-Tsyr Lin, Helena Folly-Kossi, Shwu-Jiuan Lin, Weei-Chin Lin

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • HHS | NIH | National Cancer Institute
  • U.S. Department of Defense
  • Rivkin Center for Ovarian Cancer
  • HHS | NIH | National Institute of General Medical Sciences

Zitieren

APA

Lin, F. T., Liu, K., Garan, L. A. W., Folly-Kossi, H., Song, Y., Lin, S. J., & Lin, W. C. (2023). A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proceedings of the National Academy of Sciences, 120(44). https://doi.org/10.1073/pnas.2307793120

Vancouver

Lin FT, Liu K, Garan LAW, Folly-Kossi H, Song Y, Lin SJ, et al. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proceedings of the National Academy of Sciences. 2023;120(44). doi:10.1073/pnas.2307793120

BibTeX
@article{Lin2023,
  author = {Lin, Fang-Tsyr and Liu, Kang and Garan, Lidija A Wilhelms and Folly-Kossi, Helena and Song, Yongcheng and Lin, Shwu-Jiuan and Lin, Weei-Chin},
  title = {A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {44},
  doi = {10.1073/pnas.2307793120}
}
Kostenlos starten →